Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Renal Cell 10Neoplasms 8Neoplasm Metastasis 8Endometrial Neoplasms 6Breast Neoplasms 6Brain Neoplasms 5Unspecified Adult Solid Tumor, Protocol Specific 4Prostatic Neoplasms 4Melanoma 4Lymphoma 4Kidney Neoplasms 4Glioblastoma 4Advanced Cancer 4Uterine Cervical Neoplasms 3Sarcoma 3Recurrence 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Multiple Myeloma 3Glioma 3Central Nervous System Neoplasms 3Unspecified Childhood Solid Tumor, Protocol Specific 2Solid Tumors 2Small Cell Lung Carcinoma 2Resistant Solid Malignancies 2Pinealoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Oligodendroglioma 2Lymphoma, Mantle-Cell 2Lung Neoplasms 2

Interventions

temsirolimus 1rofecoxib 1rindopepimut 1ovex 1entinostat 1cixutumumab 1azurin (50-77) 1Piperazine 1Mebendazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Brain Stem Neoplasms × temsirolimus × Clear all
NCT01182883 2017-07-02

A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
CNS

Glioma, Pinealoma, Brain Stem Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡